ATR

AptarGroup, Inc. 2006 Annual Report (10-K) Summary

Business Context and Reporting Period

This report covers the fiscal year ended December 31, 2006. AptarGroup, Inc. is a leading global supplier of innovative dispensing systems (pumps, closures, and aerosol valves) for the personal care, fragrance/cosmetic, pharmaceutical, household, and food/beverage markets. The company operates through three reportable segments: Beauty & Home, Pharma, and Closures. In 2006, the company marked its 41st consecutive year of revenue growth.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 16% to over $1.6 billion, driven by a resurgence in the fragrance/cosmetics market, acquisitions (contributing ~7% of growth), and increased demand for innovative dispensing systems. Currency fluctuations contributed approximately 1% to sales growth.
• Margin Compression: Operating margin decreased to 10.1% from 10.9%. This was primarily due to the adoption of SFAS 123R (stock option expensing), which reduced operating income by $13.3 million, and rising raw material costs (plastic resin and metals) that were only partially passed through to customers.
• Segment Performance:
  • Beauty & Home: Sales up 20% and Segment Income up 34%, led by strong fragrance/cosmetic demand.
  • Closures: Sales up 15%, but Segment Income grew only 3.9% due to operational difficulties at a French facility and lower-margin product mix.
  • Pharma: Sales up 9% and Segment Income up 6.4%, driven by Metered Dose Inhaler (MDI) sales offsetting softness in nasal spray pumps.
• Acquisitions: The company acquired CCL Dispensing Systems, Augros do Brasil, and Engelmann (remaining interest), and Graphocolor (remaining interest), adding approximately $92 million in sales.

Guidance, Outlook, and Risks

• Outlook: Management anticipates strong demand continuing into 2007. They expect diluted EPS for Q1 2007 to range from $0.69 to $0.74. The effective tax rate for 2007 is expected to be 31% to 32%.
• Stock-Based Compensation: The pretax impact of stock option expensing is expected to increase to approximately $14.1 million in 2007 compared to $13.3 million in 2006.
• Capital Expenditures: Estimated at $137 million for 2007, with 25% allocated to new product introductions.
• Key Risks:
  • Raw Material Costs: Continued volatility in plastic resin and metal prices with potential inability to pass costs to customers.
  • Competition: Intense price competition, particularly from low-cost Asian suppliers in the fragrance and personal care markets.
  • Currency: Significant exposure to the Euro; a strengthening dollar could dilute results, while a weakening dollar increases the cost of imported European products.
  • Goodwill Impairment: The company holds $207.9 million in goodwill. A $1.6 million impairment was recorded in 2006 for an R&D unit. Further impairments could occur if cash flow estimates decline.

Investor Verification Checklist

• Stock Option Expense Impact: Verify the trajectory of non-cash stock-based compensation expenses under SFAS 123R and their effect on future EPS.
• Raw Material Pass-Through: Assess the company's ability to maintain margins given rising resin and metal costs and competitive pricing pressure.
• French Operations: Monitor the resolution of operational difficulties and the progress of the redeployment program at the French Closures facility.
• Goodwill Valuation: Review the assumptions used in the annual goodwill impairment test, particularly for the reporting unit with the smallest excess of fair value over carrying value.
• Foreign Currency Hedging: Evaluate the effectiveness of hedging strategies given the company's significant Euro exposure and the volatility of the USD/EUR exchange rate.